New advances in the targeted therapy of EGFR exon20ins mutant advanced NSCLC
10.3760/cma.j.cn371439-20250217-00065
- VernacularTitle:EGFR ex20ins突变型晚期NSCLC靶向治疗新进展
- Author:
Chun YUAN
1
;
Xuesong YU
;
Mengchao WANG
;
Shao ZHANG
;
Yanbo HUANG
;
Chaoran WANG
;
Fanming KONG
;
Liwei CHEN
Author Information
1. 天津中医药大学第一附属医院肿瘤科 国家中医针灸临床医学研究中心 天津市中医肿瘤研究所，天津 300380
- Keywords:
Carcinoma, non-small-cell lung;
Genes, erbB-1;
Molecular targeted therapy
- From:
Journal of International Oncology
2025;52(6):382-387
- CountryChina
- Language:Chinese
-
Abstract:
The epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutation is a rare subtype of mutations in non-small cell lung cancer (NSCLC). Patients with advanced NSCLC carrying the EGFR ex20ins mutation tend to have poor responses to traditional EGFR tyrosine kinase inhibitors (TKIs), chemotherapy, and immunotherapy, leading to a poor clinical prognosis. Significant progress has been made in the development of new drugs targeting the EGFR ex20ins mutation. The research on new drugs targeting EGFR ex20ins mutations has made significant progress. The main ones include new EGFR-TKIs (such as sunvozertinib, mobocertinib, and furmetinib, etc.), bispecific antibodies (such as amivantamab, JMT101, and GB263T, etc.), and emerging drugs such as AUY922. These agents have demonstrated promising efficacy in clinical trials, improving the objective response rate and progression-free survival of patients, and are expected to improve overall survival. An in-depth analysis of the mechanism of action and clinical trial progress of these novel targeted drugs for EGFR ex20ins-mutated NSCLC can offer new therapeutic strategies for patients with EGFR ex20ins-mutated NSCLC.
